Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Anna Scowcroft"'
Autor:
Ella Nysetvold, Lauren N. Lopez, Ashley N. Cogell, Henrik Fryk, Nelson D. Pace, Sara Snell Taylor, Joyce Rhoden, Caitlin A. Nichols, Demetris Pillas, Alexander Klein, Teresa Gasalla, Anna Scowcroft
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 19, Iss 1, Pp 1-14 (2024)
Abstract Background Progressive supranuclear palsy (PSP) is a rare neurodegenerative brain disease with rapid progression and currently limited treatment options. A comprehensive understanding of disease progression, management, and healthcare resour
Externí odkaz:
https://doaj.org/article/6e2aa388272d41f587cb0d60a0d93ee8
Autor:
Milada Mahic, Ali Bozorg, Jonathan DeCourcy, Keisha Golden, Gregor Gibson, Christian Taylor, Anna Scowcroft
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 18, Iss 1, Pp 1-17 (2023)
Abstract Background Myasthenia gravis (MG) is a rare, chronic, debilitating, unpredictable, and potentially life-threatening neuromuscular disease. There is a lack of real-world data on disease management that could be used to further understand and
Externí odkaz:
https://doaj.org/article/8396810285704f1b805a253d10b9b50b
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 16 (2023)
Background: There are limited data on the impact of myasthenia gravis (MG) on real-world healthcare resource use (HCRU) and patient burden in the United States. Objectives: This study aims to assess HCRU in patients with MG using data from a US healt
Externí odkaz:
https://doaj.org/article/6db0f71c20fd4d26b3378f40d1c2e134
Autor:
Demetris Pillas, Alexander Klein, Teresa Gasalla, Andreja Avbersek, Alexander Thompson, Jack Wright, Jennifer Mellor, Anna Scowcroft
Publikováno v:
Frontiers in Neurology, Vol 13 (2022)
Progressive supranuclear palsy (PSP) is a rare, relentlessly progressive, ultimately fatal neurodegenerative brain disease. The objective of this study was to assess the burden of PSP on patients, caregivers, and healthcare systems by PSP phenotype.
Externí odkaz:
https://doaj.org/article/d3703f92a5e045cdbe5d3b3e67b8575a
Autor:
Ian D. Pavord, Nicola Mathieson, Anna Scowcroft, Riccardo Pedersini, Gina Isherwood, David Price
Publikováno v:
npj Primary Care Respiratory Medicine, Vol 27, Iss 1, Pp 1-8 (2017)
Asthma: Drug combo leaves many with uncontrolled disease Many people who take inhaled steroids combined with long-acting β2-agonist drugs still have poorly controlled asthma. A team led by Ian Pavord from the University of Oxford, UK, identified 701
Externí odkaz:
https://doaj.org/article/0d36bb18ba614775b04b5f1fea03b7ec
Publikováno v:
Muscle & Nerve. 67:297-305
Autor:
Milada Mahic, Ali M. Bozorg, Jonathan J. DeCourcy, Keisha J. Golden, Gregor A. Gibson, Christian F. Taylor, Angela Ting, Tyler J. Story, Anna Scowcroft
Publikováno v:
Neurology and Therapy. 11:1535-1551
Myasthenia gravis (MG) is a rare, debilitating, chronic disorder caused by the production of pathogenic immunoglobulin G autoantibodies against the neuromuscular junction. A lack of real-world studies in rare diseases reflects a relatively limited un
Autor:
Demetris Pillas, Alexander Klein, Teresa Gasalla, Andreja Avbersek, Alexander Thompson, Jack Wright, Jennifer Mellor, Anna Scowcroft
Publikováno v:
Frontiers in neurology. 13
Progressive supranuclear palsy (PSP) is a rare, relentlessly progressive, ultimately fatal neurodegenerative brain disease. The objective of this study was to assess the burden of PSP on patients, caregivers, and healthcare systems by PSP phenotype.
Autor:
Abigail Tebboth, Anna Scowcroft, John Bolodeoku, William Spencer, Paula Bingham-Gardiner, Syed Wasi Hassan, Sally Lee
Publikováno v:
Clinical Therapeutics. 39:1266-1270
Autor:
Anna Scowcroft, Gina Isherwood, Riccardo Pedersini, Nicola Mathieson, David Price, Ian D. Pavord
Publikováno v:
npj Primary Care Respiratory Medicine, Vol 27, Iss 1, Pp 1-8 (2017)
NPJ Primary Care Respiratory Medicine
NPJ Primary Care Respiratory Medicine
There are several new treatment options for patients whose asthma remains uncontrolled on free-dose and fixed-dose combinations of inhaled corticosteroids plus long-acting β2-agonists (ICS+LABA). In order to evaluate the likely impact of these treat